# Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease

> **NCT07719543** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 146 (estimated)

## Conditions studied

- Immunoglobulin G4-Related Disease

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07719543
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2026-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07719543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07719543, "Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07719543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*